Sept 25 (Reuters) - AbbVie Inc (NYSE:ABBV) ABBV.N :
* ABBVIE RECEIVES APPROVAL FROM HEALTH CANADA FOR THE COMBINATION OF VENCLEXTA® WITH RITUXIMAB AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
* ABBVIE INC - APPROVAL IS BASED ON MURANO PHASE 3 CLINICAL TRIAL DATA